Last reviewed · How we verify
NCT07163000: ACT
Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)
trial in Peripheral Neuropathy in 150 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2026
Quick facts
| Lead sponsor | Weill Cornell Medical College in Qatar |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 11 May 2025 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across Qatar |
Conditions studied
- Peripheral Neuropathy — all drugs for Peripheral Neuropathy →
- Painful Neuropathy — all drugs for Painful Neuropathy →
- Diabetes (DM) — all drugs for Diabetes (DM) →
Sponsor
Weill Cornell Medical College in Qatar
Who can join
18 and older, any sex, with Peripheral Neuropathy or Painful Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is looking at people with diabetes (type 1 and type 2 diabetes) to see how well a short questionnaire, called the ACT, can identify nerve damage in the feet and legs (also known as peripheral neuropathy). The investigators will compare the ACT questionnaire to other commonly used tools (the DN4 and Michigan Neuropathy Screening Instrument) and to an eye-test that detects small nerve fibers in the eye (called corneal confocal microscopy, or CCM). The main goal is to find out if the ACT questionnaire is accurate in detecting nerve damage and painful nerve damage caused by diabetes. The investigators will also look at whether changes in blood sugar levels, measured with a continuous glucose monitor (Freestyle Libre 3 and iCan), are linked to nerve pain and small nerve fiber damage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07163000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Neuropathy
Currently open trials in the same condition.
- NCT07336381 — Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy · NA · recruiting
- NCT07025005 — Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VR · Phase 4 · recruiting
- NCT07055711 — Association Between Work-Related Stress and Peripheral Neuropathic Pain in Female Breast Cancer Post CT · active not recruiting
- NCT06615622 — Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic · recruiting
- NCT07019233 — A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy In · NA · recruiting
Other Weill Cornell Medical College in Qatar trials
Trials by the same sponsor.
- NCT07515807 — Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence · not yet recruiting
- NCT07521033 — Development and Assessment of a 360° Video-Based Virtual Reality Application to Enhance Medical Students' Preparation fo · NA · completed
- NCT04573101 — EEG Responses to Arabic Music Scales · NA · completed
- NCT03349840 — Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan · Phase 4 · terminated
- NCT03225339 — Diabetes Intervention Accentuating Diet and Enhancing Metabolism · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07163000 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Weill Cornell Medical College in Qatar
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07163000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing